Royal Bank of Canada’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-798
| Closed | -$2K | – | 7887 |
|
|
2023
Q4 | $2K | Buy |
798
+544
| +214% | +$1.09K | ﹤0.01% | 6869 |
|
|
2023
Q3 | $1K | Sell |
254
-504
| -66% | -$1.24K | ﹤0.01% | 7005 |
|
|
2023
Q2 | $2K | Buy |
758
+757
| +75,700% | +$4.03K | ﹤0.01% | 6942 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7732 |
|
|
2022
Q4 | $0 | Buy |
+1
| New | +$12 | ﹤0.01% | 8046 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 8125 |
|
|
2022
Q2 | – | Sell |
-1
| Closed | -$145 | – | 7999 |
|
|
2022
Q1 | $0 | Sell |
1
-5
| -83% | -$3.19K | ﹤0.01% | 8185 |
|
|
2021
Q4 | $6K | Sell |
6
-399
| -99% | -$563K | ﹤0.01% | 7201 |
|
|
2021
Q3 | $779K | Sell |
405
-92
| -19% | -$208K | ﹤0.01% | 3934 |
|
|
2021
Q2 | $1.32M | Buy |
497
+30
| +6% | +$98.9K | ﹤0.01% | 3419 |
|
|
2021
Q1 | $1.94M | Buy |
467
+81
| +21% | +$438K | ﹤0.01% | 3032 |
|
|
2020
Q4 | $2.21M | Buy |
386
+21
| +6% | +$124K | ﹤0.01% | 2825 |
|
|
2020
Q3 | $2.22M | Buy |
365
+40
| +12% | +$229K | ﹤0.01% | 2607 |
|
|
2020
Q2 | $1.81M | Buy |
325
+37
| +13% | +$192K | ﹤0.01% | 2700 |
|
|
2020
Q1 | $1.07M | Buy |
288
+106
| +58% | +$608K | ﹤0.01% | 2975 |
|
|
2019
Q4 | $911K | Buy |
182
+56
| +44% | +$196K | ﹤0.01% | 3518 |
|
|
2019
Q3 | $299K | Buy |
126
+12
| +11% | +$29.6K | ﹤0.01% | 4186 |
|
|
2019
Q2 | $333K | Sell |
114
-2
| -2% | -$5.58K | ﹤0.01% | 4132 |
|
|
2019
Q1 | $349K | Sell |
116
-9
| -7% | -$19.1K | ﹤0.01% | 3992 |
|
|
2018
Q4 | $143K | Sell |
125
-43
| -26% | -$65.9K | ﹤0.01% | 4545 |
|
|
2018
Q3 | $123K | Sell |
168
-19
| -10% | -$13.9K | ﹤0.01% | 4752 |
|
|
2018
Q2 | $184K | Buy |
187
+24
| +15% | +$84.2K | ﹤0.01% | 4455 |
|
|
2018
Q1 | $838K | Buy |
163
+7
| +4% | +$46.3K | ﹤0.01% | 3298 |
|
|
2017
Q4 | $838K | Buy |
156
+88
| +129% | +$820K | ﹤0.01% | 3365 |
|
|
2017
Q3 | $606K | Buy |
68
+52
| +325% | +$399K | ﹤0.01% | 3652 |
|
|
2017
Q2 | $122K | Buy |
16
+14
| +700% | +$96.9K | ﹤0.01% | 4658 |
|
|
2017
Q1 | $15K | Hold |
2
| – | – | ﹤0.01% | 5782 |
|
|
2016
Q4 | $28K | Hold |
2
| – | – | ﹤0.01% | 5585 |
|
|
2016
Q3 | $34K | Hold |
2
| – | – | ﹤0.01% | 5331 |
|
|
2016
Q2 | $37K | Hold |
2
| – | – | ﹤0.01% | 5242 |
|
|
2016
Q1 | $30K | Hold |
2
| – | – | ﹤0.01% | 5341 |
|
|
2015
Q4 | $48K | Sell |
2
-1
| -33% | -$15.8K | ﹤0.01% | 5326 |
|
|
2015
Q3 | $35K | Hold |
3
| – | – | ﹤0.01% | 5319 |
|
|
2015
Q2 | $48K | Buy |
3
+1
| +50% | +$21.3K | ﹤0.01% | 5238 |
|
|
2015
Q1 | $45K | Hold |
2
| – | – | ﹤0.01% | 5022 |
|
|
2014
Q4 | $27K | Sell |
2
-1
| -33% | -$12.7K | ﹤0.01% | 5305 |
|
|
2014
Q3 | $37K | Buy |
+3
| New | +$46.3K | ﹤0.01% | 5084 |
|
Other funds holding AGRX
Royal Bank of Canada's AGRX Position: Q1 2024 in Review
Royal Bank of Canada sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 798 shares — an estimated $2K sold.
Royal Bank of Canada first reported a position in AGRX in Q3 2014 and held it in 36 quarters. The position peaked at $2.22M in Q3 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- Royal Bank of Canada reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- Royal Bank of Canada sold 798 Agile Therapeutics shares in Q1 2024, an estimated $2K.
- Royal Bank of Canada first reported a position in Agile Therapeutics in Q3 2014 and held it in 36 quarters.
- Royal Bank of Canada's Agile Therapeutics position peaked at $2.22M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.